Continued here: Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program
Continued here: Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program
Follow this link: Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024
See the original post here: Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
Read this article: Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024
View original post here: Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7
Go here to read the rest: Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024
More: Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency...
Targeting the stem cell niche micro-environment as therapeutic strategies in aging Frontiers
International trial introduces another curative option for sickle cell disease EurekAlert
HOX genes in stem cells: Maintaining cellular identity and regulation of differentiation Frontiers
Recent Comments